Advertisement
IMUX vs ORIC
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMUX is a Hold and ORIC is a StrongBuy.
IMUX's RSI Oscillator ascending out of oversold territory
The RSI Oscillator for IMUX moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 30 similar instances when the indicator left oversold territory. In 27 of the 30 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 58 of 63 cases where IMUX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Moving Average Convergence Divergence (MACD) for IMUX just turned positive on October 15, 2026. Looking at past instances where IMUX's MACD turned positive, the stock continued to rise in 34 of 41 cases over the following month. The odds of a continued upward trend are 83%.
Following a +7.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMUX advanced for three days, in 218 of 257 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
IMUX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMUX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for IMUX entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.800) is normal, around the industry mean (2.988). P/E Ratio (-2.107) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. IMUX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMUX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
ORIC in upward trend: price rose above 50-day moving average on October 20, 2026
ORIC moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend. In 31 of 35 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ORIC's RSI Oscillator exited the oversold zone, 35 of 40 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on ORIC as a result. In 67 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for ORIC just turned positive on October 19, 2026. Looking at past instances where ORIC's MACD turned positive, the stock continued to rise in 37 of 42 cases over the following month. The odds of a continued upward trend are 88%.
Following a +8.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where ORIC advanced for three days, in 214 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The 10-day moving average for ORIC crossed bearishly below the 50-day moving average on October 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 73%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ORIC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
ORIC broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ORIC entered a downward trend on September 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.765) is normal, around the industry mean (2.988). P/E Ratio (-10.654) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. ORIC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 79 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ORIC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
IMUX | ORIC | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 9 | 25 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 31 Undervalued | 18 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 99 | 97 | |
PRICE GROWTH RATING 1..100 | 85 | 39 | |
P/E GROWTH RATING 1..100 | 9 | 79 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ORIC's Valuation (18) in the null industry is in the same range as IMUX (31) in the Pharmaceuticals Major industry. This means that ORIC’s stock grew similarly to IMUX’s over the last 12 months.
ORIC's Profit vs Risk Rating (100) in the null industry is in the same range as IMUX (100) in the Pharmaceuticals Major industry. This means that ORIC’s stock grew similarly to IMUX’s over the last 12 months.
ORIC's SMR Rating (97) in the null industry is in the same range as IMUX (99) in the Pharmaceuticals Major industry. This means that ORIC’s stock grew similarly to IMUX’s over the last 12 months.
ORIC's Price Growth Rating (39) in the null industry is somewhat better than the same rating for IMUX (85) in the Pharmaceuticals Major industry. This means that ORIC’s stock grew somewhat faster than IMUX’s over the last 12 months.
IMUX's P/E Growth Rating (9) in the Pharmaceuticals Major industry is significantly better than the same rating for ORIC (79) in the null industry. This means that IMUX’s stock grew significantly faster than ORIC’s over the last 12 months.
| IMUX | ORIC | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 88% |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 89% |
| Momentum ODDS (%) | N/A | 2 days ago 86% |
| MACD ODDS (%) | 2 days ago 83% | 2 days ago 88% |
| TrendWeek ODDS (%) | 2 days ago 87% | 2 days ago 85% |
| TrendMonth ODDS (%) | 2 days ago 87% | 2 days ago 83% |
| Advances ODDS (%) | 2 days ago 85% | 2 days ago 85% |
| Declines ODDS (%) | 9 days ago 86% | 10 days ago 84% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 77% |
| Aroon ODDS (%) | 2 days ago 84% | 2 days ago 85% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IMUX’s FA Score shows that 2 FA rating(s) are green while ORIC’s FA Score has 1 green FA rating(s).
- IMUX’s FA Score: 2 green, 3 red.
- ORIC’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IMUX’s TA Score shows that 5 TA indicator(s) are bullish while ORIC’s TA Score has 5 bullish TA indicator(s).
- IMUX’s TA Score: 5 bullish, 2 bearish.
- ORIC’s TA Score: 5 bullish, 5 bearish.
Price Growth
IMUX (@Biotechnology) experienced а +12.31% price change this week, while ORIC (@Biotechnology) price change was +19.50% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.02%. For the same industry, the average monthly price growth was -18.10%, and the average quarterly price growth was -15.28%.
Reported Earning Dates
IMUX is expected to report earnings on Nov 12, 2026.
ORIC is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Biotechnology (-1.02% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
IMUX and
Correlation & Price change
A.I.dvisor indicates that over the last year, IMUX has been loosely correlated with VYGR. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if IMUX jumps, then VYGR could also see price increases.
| Ticker / NAME | Correlation To IMUX | 1D Price Change % | ||
|---|---|---|---|---|
| IMUX | 100% | +0.94% | ||
| VYGR - IMUX | 38% Loosely correlated | -7.76% | ||
| NAMS - IMUX | 36% Loosely correlated | -0.05% | ||
| CCCC - IMUX | 35% Loosely correlated | +0.32% | ||
| ERAS - IMUX | 35% Loosely correlated | -0.89% | ||
| VIR - IMUX | 35% Loosely correlated | -1.58% | ||
More | ||||
ORIC and
Correlation & Price change
A.I.dvisor indicates that over the last year, ORIC has been loosely correlated with REPL. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if ORIC jumps, then REPL could also see price increases.
| Ticker / NAME | Correlation To ORIC | 1D Price Change % | ||
|---|---|---|---|---|
| ORIC | 100% | +0.51% | ||
| REPL - ORIC | 37% Loosely correlated | +2.63% | ||
| TRVI - ORIC | 37% Loosely correlated | -0.47% | ||
| RKTO - ORIC | 37% Loosely correlated | -1.11% | ||
| WVE - ORIC | 36% Loosely correlated | -1.46% | ||
| RCUS - ORIC | 35% Loosely correlated | -19.58% | ||
More | ||||